Thursday, November 21, 2024

No Result

View All Result

Media

Support Us

No Result

View All Result

Health

No rare disorder sufferer should be left behind – The troubling case of spinal muscular atrophy: Nigel Rawson and John Adams in National Newswatch

October 30, 2024

Nigel Rawson

When suicide attempts turn into assisted suicides: Alexander Raikin for Inside Policy

Columns

Government hostility to biopharmaceutical industry reduces access to innovative drugs: Nigel Rawson and John Adams in the Hill Times

November 16, 2023

Columns

Pharmacare won’t help Canadians with rare disorders: Nigel Rawson and John Adams in the Financial Post

November 7, 2023

Columns

Americans look to Canada for lower drug prices, but are they getting the full picture?: Nigel Rawson and John Adams in The Hill

October 7, 2023

Commentary

Waiting for new drugs for rare disorders in Canada

September 6, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 8 – need for a national strategy: Nigel Rawson and John Adams for Inside Policy

August 30, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 7 – Canadian Drug Agency: Nigel Rawson and John Adams for Inside Policy

August 23, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 6 – national pharmacare: Nigel Rawson and John Adams for Inside Policy

August 16, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 5 – Patented Medicine Prices Review Board: Nigel Rawson and John Adams for Inside Policy

August 9, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 4 – government drug plan listing: Nigel Rawson and John Adams for Inside Policy

August 2, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 3, price negotiation: Nigel Rawson and John Adams for Inside Policy

July 26, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 2, health technology assessment: Nigel Rawson and John Adams for Inside Policy

July 19, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 1, regulatory approval: Nigel Rawson and John Adams for Inside Policy

July 12, 2023

Page 2 of 3 Prev 1 2 3 Next

Newsletter Signup

Email Address *

First Name *

Last Name *

*Required Fields

Follow us on

Macdonald-Laurier Institute

Support Us

Support the Macdonald-Laurier Institute to help ensure that Canada is one of the best governed countries in the world. Click below to learn more or become a sponsor.

Support Us

No Result

View All Result

No rare disorder sufferer should be left behind – The troubling case of spinal muscular atrophy: Nigel Rawson and John Adams in National Newswatch

Nigel Rawson

Government hostility to biopharmaceutical industry reduces access to innovative drugs: Nigel Rawson and John Adams in the Hill Times

Pharmacare won’t help Canadians with rare disorders: Nigel Rawson and John Adams in the Financial Post

Americans look to Canada for lower drug prices, but are they getting the full picture?: Nigel Rawson and John Adams in The Hill

Waiting for new drugs for rare disorders in Canada

Waiting for new drugs for rare disorders in Canada, part 8 – need for a national strategy: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 7 – Canadian Drug Agency: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 6 – national pharmacare: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 5 – Patented Medicine Prices Review Board: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 4 – government drug plan listing: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 3, price negotiation: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 2, health technology assessment: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 1, regulatory approval: Nigel Rawson and John Adams for Inside Policy

Top News

Mexican cartels are a direct threat to Canada’s public safety, and the future of North American trade: Gary J. Hale for Inside Policy

Hostages, Tunnels, and Urban Combat: Israel’s Fight Against Hamas and Hezbollah

Canada’s foreign policy needs a radical reset. Here are the three things a new government should focus on first: David Mulroney in the Hub

Multimedia

The evolving battlegrounds of free speech: Peter Copeland and Kristopher Kinsinger for Inside Policy Talks

The Prelude to Genocide: Antisemitism, Memory and Moral Urgency in Canada

Tim Sargent on Canada’s anemic growth and productivity: MLI in Parliament

Canada is disintegrating: Eric Kaufmann in the Telegraph

European North: NATO’s new northern flank

Canada’s dirty money is funding instability in the Middle East: Christian Leuprecht and Joe Adam George in the Globe and Mail

‘We should all take a valium’ – Why Canadians should calm down about Trump: Brian Lee Crowley in the National Post

Israel’s war may soon end. Ours is just beginning: Casey Babb in the National Post

Newsletter Signup

Follow us on

Macdonald-Laurier Institute

Support Us